Entellus Medical Inc (NASDAQ:ENTL) VP Thomas P. Williamson sold 2,449 shares of Entellus Medical stock in a transaction on Monday, January 8th. The stock was sold at an average price of $24.08, for a total transaction of $58,971.92. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Thomas P. Williamson also recently made the following trade(s):
- On Friday, January 5th, Thomas P. Williamson sold 968 shares of Entellus Medical stock. The stock was sold at an average price of $24.01, for a total transaction of $23,241.68.
Entellus Medical Inc (NASDAQ:ENTL) opened at $24.07 on Wednesday. Entellus Medical Inc has a fifty-two week low of $11.47 and a fifty-two week high of $25.58. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.92 and a quick ratio of 1.71. The firm has a market cap of $618.89, a price-to-earnings ratio of -18.66 and a beta of 0.02.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ENTL. Schwab Charles Investment Management Inc. increased its holdings in Entellus Medical by 33.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 37,799 shares of the medical technology company’s stock valued at $626,000 after buying an additional 9,469 shares in the last quarter. Rhumbline Advisers purchased a new position in Entellus Medical in the second quarter valued at $199,000. Bank of New York Mellon Corp increased its holdings in Entellus Medical by 29.4% in the second quarter. Bank of New York Mellon Corp now owns 40,783 shares of the medical technology company’s stock valued at $675,000 after buying an additional 9,270 shares in the last quarter. Neuberger Berman Group LLC purchased a new position in Entellus Medical in the second quarter valued at $381,000. Finally, Keybank National Association OH increased its holdings in Entellus Medical by 11.0% in the second quarter. Keybank National Association OH now owns 32,594 shares of the medical technology company’s stock valued at $540,000 after buying an additional 3,235 shares in the last quarter. 78.24% of the stock is owned by institutional investors.
ENTL has been the subject of several recent research reports. William Blair cut shares of Entellus Medical from an “outperform” rating to a “market perform” rating in a report on Friday, December 8th. ValuEngine raised shares of Entellus Medical from a “sell” rating to a “hold” rating in a report on Thursday, December 7th. Zacks Investment Research cut shares of Entellus Medical from a “buy” rating to a “hold” rating in a report on Tuesday, October 31st. TheStreet raised shares of Entellus Medical from a “d” rating to a “c-” rating in a report on Thursday, December 14th. Finally, Canaccord Genuity reissued a “hold” rating and set a $17.00 target price on shares of Entellus Medical in a report on Tuesday, October 17th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $19.25.
TRADEMARK VIOLATION WARNING: This piece was posted by BBNS and is the sole property of of BBNS. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://baseballnewssource.com/markets/entellus-medical-inc-entl-vp-thomas-p-williamson-sells-2449-shares-of-stock/1822448.html.
About Entellus Medical
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.